MarketCapExport financials
Processa Pharmaceuticals (PCSA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Processa Pharmaceuticals Financial Ratios 2025-2011 | PCSA
Brief overview of Processa Pharmaceuticals's market valuation
Current figures are compared with the company's own five-year history for 2021–2025.
The latest available valuation ratios are P/S 332.72x (median 95.13x), P/B 0.74x (median 0.62x). Multiples are on average 134.4% above their own medians. A substantial share of positive expectations may already be priced in.
Returns on assets and capital are represented by ROE -2.4%, ROA -173.6%, ROCE -2.5%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
The cash conversion cycle decreased 571.9 days to -461.8 days, supporting working-capital efficiency.
Overall assessment
Processa Pharmaceuticals's market premium is not yet supported by strong capital returns, raising valuation risk.
Annual Financial Ratios Processa Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.3 | -0.0 | -0.3 | -0.0 | -5.1 | -2.4 | -13.6 | -31.7 | -72.0 | -5.0 | -1.3 | -4.2 | - | - | - | |
P/S |
- | - | - | - | - | - | - | - | - | 332.7 | 38.8 | 95.1 | - | - | - |
EPS |
-10.4 | -96.8 | -8.5 | -34.0 | -0.8 | -2.5 | -0.7 | -0.7 | -0.1 | -0.1 | -0.3 | -0.7 | -0.6 | -1.5 | - |
EV (Enterprise Value) |
837 K | 729 K | -800 K | -4.98 M | 43.2 M | 22.1 M | 47.8 M | 121 M | 133 M | 2.95 M | 6.49 M | 20.4 M | 1.08 M | 300 K | 2.53 M |
EBITDA per Share |
-10.7 | -98.4 | -8.74 | -33.2 | -0.79 | -1.01 | -0.567 | -0.73 | -0.387 | -0.317 | -3.33 | -13.8 | - | - | - |
EV/EBITDA |
-0.1 | -0.1 | 0.1 | 0.2 | -2.5 | -3.6 | -14.6 | -30.3 | -74.0 | -45.9 | -7.7 | -8.0 | - | - | - |
PEG |
-0.0 | -0.0 | -0.0 | -0.0 | -0.18 | 0.01 | -95032.06 | 0.48 | -1.01 | -0.05 | -0.02 | 0.37 | - | - | - |
P/B |
0.7 | 0.2 | 0.6 | 0.0 | 2.3 | 1.5 | 5.7 | 12.3 | 358.1 | -0.7 | -2.2 | 15.8 | - | - | - |
P/CF |
-0.4 | -0.0 | -0.4 | -0.0 | -6.7 | -11.2 | -16.6 | -32.0 | -79.8 | -38.5 | -5.0 | -6.9 | - | - | - |
ROE % |
-243.20 | -698.64 | -222.91 | -367.09 | -44.84 | -62.83 | -41.91 | -38.81 | -497.45 | 14.29 | 169.51 | -374.71 | - | - | - |
ROA % |
-173.59 | -366.96 | -192.19 | -318.15 | -43.18 | -57.16 | -30.85 | -28.49 | -62.23 | -10379.43 | -3215.29 | -178.05 | - | - | - |
ROCE % |
-250.81 | -710.49 | -229.64 | -368.44 | -47.61 | -26.83 | -40.61 | -36.00 | -470.45 | 3.04 | 49.89 | -173.18 | - | - | - |
Current Ratio |
3.5 | 2.1 | 7.3 | 7.5 | 27.0 | 13.3 | 0.8 | 3.1 | 1.1 | 0.0 | 0.1 | 0.5 | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | 7.5 | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | 715.5 | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | 461.8 | 612.9 | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | 723.0 | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | -461.8 | 110.1 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Processa Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.29 | -0.07 | -0.25 | -0.3 | - | -1.03 | -1.01 | -1.11 | - | -1.54 | -1.94 | -0.18 | - | -0.37 | -0.32 | -0.2 | - | -0.19 | -0.2 | -0.14 | - | -0.55 | -0.13 | -0.16 | - | -0.16 | -0.18 | -0.14 | - | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.03 | -0.02 | -0.01 | - | -0.03 | -0.19 | -0.06 | - | -0.1 | -0.11 | -0.17 | - | -0.12 | -0.34 | -0.48 | - | -0.4 | -0.31 | - | - | - | - | - |
EBITDA per Share |
-1.27 | - | - | -0.3 | - | - | - | -1.14 | - | - | - | - | - | -0.36 | -0.3 | -0.19 | - | -0.2 | -0.22 | -0.15 | - | -0.53 | -0.14 | -0.18 | - | -0.18 | -0.21 | -0.16 | - | -0.03 | -0.04 | -0.04 | - | -0.02 | -0.01 | -0.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.01 | 0.01 | - | - | - | - | - | - | - | - |
ROE % |
-336.61 | -294.66 | -285.73 | -252.01 | -171.63 | -200.68 | -138.23 | -127.92 | -97.22 | -132.15 | -128.82 | -114.18 | -74.53 | -85.50 | -61.38 | -42.36 | -28.48 | -41.86 | -34.08 | -27.10 | -20.40 | -31.17 | -29.88 | -36.05 | -32.24 | -41.03 | -42.69 | -41.90 | -32.53 | -202.39 | -384.29 | -446.47 | -497.45 | -317.26 | -91.38 | 7.67 | 81.91 | 86.52 | 154.98 | 163.12 | 151.17 | 85.61 | 0.20 | -214.74 | -247.32 | -290.34 | -268.26 | -246.65 | -135.36 | -158.85 | -134.37 | -48.86 | - | -23.49 | -18.54 | - | - | - | - | - |
ROA % |
-227.02 | -220.81 | -215.10 | -192.78 | -133.85 | -159.74 | -123.61 | -84.00 | -84.00 | -116.36 | -114.45 | -101.84 | -69.49 | -79.78 | -57.56 | -40.01 | -26.73 | -38.91 | -31.53 | -24.85 | -18.56 | -26.49 | -23.22 | -27.21 | -23.74 | -30.57 | -32.30 | -32.18 | -25.29 | -46.53 | -63.56 | -63.23 | -62.23 | -50.89 | -25586.69 | -43322.55 | -51994.06 | -52267.65 | -28674.14 | -11546.85 | -2867.55 | -2898.70 | -2648.70 | -735.43 | -117.52 | -141.99 | -135.56 | -129.86 | -76.98 | -92.48 | -80.24 | -27.79 | - | -15.50 | -12.23 | - | - | - | - | - |
ROCE % |
-336.33 | -297.27 | -288.63 | -255.57 | -174.84 | -205.08 | -142.67 | -131.98 | -100.36 | -135.49 | -131.00 | -115.26 | -74.78 | -86.22 | -62.92 | -44.16 | -30.27 | -43.15 | -35.21 | -27.68 | -20.68 | -33.21 | -34.52 | -42.03 | -37.73 | -48.69 | -50.88 | -50.01 | -38.99 | -230.02 | -294.19 | -342.16 | -328.84 | -191.03 | -75.12 | -62.69 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
2.3 | 4.3 | 3.9 | 3.8 | 2.1 | 4.0 | 4.8 | - | 7.3 | 8.8 | 10.8 | 5.4 | 7.5 | 13.6 | 13.7 | 22.8 | 27.1 | 16.0 | 16.4 | 16.6 | 11.1 | 11.1 | 11.1 | 11.1 | 3.8 | 3.8 | 3.8 | 3.8 | 4.5 | 4.5 | 4.5 | 4.5 | 1.1 | 1.1 | 1.1 | 1.1 | 24.2 | - | - | - | 0.1 | 0.1 | 0.1 | 0.1 | 1.9 | 1.9 | 1.9 | 1.9 | 2.3 | 2.3 | 2.3 | 2.3 | 2.9 | 2.9 | 2.9 | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 69.2 | 28.1 | 9.0 | - | 22.5 | 4.8 | 142.8 | - | 14.8 | 18.2 | 118.0 | - | 57.2 | 14.3 | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 69.2 | 28.1 | 9.0 | - | 22.5 | 4.8 | 142.8 | - | 14.8 | 18.2 | 118.0 | - | 57.2 | 14.3 | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 69.2 | 28.1 | 9.0 | - | 22.5 | 4.8 | 142.8 | - | 14.8 | 18.2 | 118.0 | - | 57.2 | 14.3 | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Processa Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Russia
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
